222 related articles for article (PubMed ID: 12879482)
1. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
3. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence.
Wu S; Gessner R; von Stackelberg A; Kirchner R; Henze G; Seeger K
Cancer; 2005 Mar; 103(5):1054-63. PubMed ID: 15651075
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
7. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.
Seeger K; Kreuzer KA; Lass U; Taube T; Buchwald D; Eckert C; Körner G; Schmidt CA; Henze G
Cancer Res; 2001 Mar; 61(6):2517-22. PubMed ID: 11289124
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
9. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia.
Wu S; Gessner R; Taube T; von Stackelberg A; Henze G; Seeger K
J Clin Oncol; 2005 May; 23(13):3038-42. PubMed ID: 15860861
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study on clinical features between TEL-AML1 positive and negative childhood acute lymphoblastic leukemia].
Guo X; Li Q; Zhu YP; Zhou CY; Gao J; Li XH; Pan LL; Li FY; Tian X; Liu HT
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Oct; 24(5):560-3. PubMed ID: 17922427
[TBL] [Abstract][Full Text] [Related]
11. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
15. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
16. Outcome of very late relapse in children with acute lymphoblastic leukemia.
Rizzari C; Valsecchi MG; Aricò M; Miniero R; Messina C; De Rossi G; Testi AM; Mura R; Galimberti S; Biondi A; Locatelli F; Conter V
Haematologica; 2004 Apr; 89(4):427-34. PubMed ID: 15075076
[TBL] [Abstract][Full Text] [Related]
17. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
18. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
19. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
Panzer-Grümayer ER; Cazzaniga G; van der Velden VH; del Giudice L; Peham M; Mann G; Eckert C; Schrauder A; Germano G; Harbott J; Basso G; Biondi A; van Dongen JJ; Gadner H; Haas OA
Clin Cancer Res; 2005 Nov; 11(21):7720-7. PubMed ID: 16278392
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
